These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30826174)

  • 41. [Meningococcal vaccines in France].
    Kernéis S; Coulange-Bodilis H; Launay O
    Rev Prat; 2016 Mar; 66(3):275-279. PubMed ID: 30512637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Parental Knowledge about Meningococcal Disease and Vaccination Uptake among 0⁻5 years Old Polish Children.
    Drozd-Dąbrowska M; Topczewska K; Korzeń M; Sałacka A; Ganczak M
    Int J Environ Res Public Health; 2019 Jan; 16(2):. PubMed ID: 30669259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
    Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
    Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can we control all-cause meningococcal disease in Europe?
    Sadarangani M; Pollard AJ
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of vaccination coverage of adolescents aged 16-18 years with an innovative electronic immunization record system.
    Gault G; Fischer A; Nicand E; Burelle F; Burbaud A; Koeck JL
    Med Mal Infect; 2019 Feb; 49(1):38-46. PubMed ID: 30527973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of vaccination on meningococcal epidemiology.
    Stefanelli P; Rezza G
    Hum Vaccin Immunother; 2016 Apr; 12(4):1051-5. PubMed ID: 26512927
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
    Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
    Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
    Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
    Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
    de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
    Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Northland emergency meningococcal C vaccination programme.
    Mills C; Penney L
    N Z Med J; 2013 Apr; 126(1373):30-9. PubMed ID: 23797074
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccines against meningococcal disease: current and future technologies.
    Riddell A; Buttery J
    Expert Opin Biol Ther; 2001 May; 1(3):385-99. PubMed ID: 11727513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.
    Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Invasive meningococcal disease in the Czech Republic - analysis of the epidemiological situation and vaccination strategy recommendations].
    Křížová P; Vacková Z; Musílek M; Kozáková J
    Epidemiol Mikrobiol Imunol; 2013 Dec; 62(4):138-47. PubMed ID: 24467175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Public health impact of Infanrix hexa (DTPa-HBV-IPV/Hib) reimbursement: A study programme in France. Part 1: Evolution of hepatitis B vaccine coverage rates in infants aged less than 27 months, in the general population - the PopCorn study.
    Gaudelus J; Vié le Sage F; Dufour V; Lert F; Texier N; Pouriel M; Tehard B; Bréart G
    Rev Epidemiol Sante Publique; 2016 Feb; 64(1):23-32. PubMed ID: 26748972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
    De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
    Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of meningococcal infections in the first 2 years of life.
    Woods CR
    Pediatr Ann; 2013 Aug; 42(8):164-71. PubMed ID: 23910030
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
    Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
    Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination.
    Perrett KP; Richmond PC; Borrow R; Nolan T; McVernon J
    Pediatr Infect Dis J; 2015 Mar; 34(3):279-85. PubMed ID: 25742078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.